Fig. 3: Oncolytic virus therapy plus anti-PD-1 antibody benefit patient with immuno-cold tumor. | Cancer Gene Therapy

Fig. 3: Oncolytic virus therapy plus anti-PD-1 antibody benefit patient with immuno-cold tumor.

From: The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient

Fig. 3

A Baseline immune cells infiltration map in four patients, showing the distribution of various immune cell types. B The abundance of NK cells between the responder and non-responders. C–F The counts of different T-cell subtypes including CD4+ Th1, CD4+ naive, CD8+ naive, and CD4+ central memory T cells in responder and non-responders. G–J The abundance of macrophages (total), M1, M2, and activated myeloid dendritic cells across the responder and non-responders. K–M Baseline TCR results in tissue and blood, presenting TCR metrics including tissue TCR, blood TCR, and the overlap between tissue and blood TCR repertoires. N–P Baseline TCR clonality and max frequency, and tissue/blood ratio of clonality and max frequency, illustrating TCR diversity (Shannon index), maximum frequency, and clonality in both tissue and blood samples. Q Difference of the number of neoantigens identified in responder and non-responder patients, indicating potential differences in immunogenicity.

Back to article page